GlassScriptPhysician profile
Nikhila Thammineni
NPI 1487150330
$1,246.32
in general payments reported to CMS, 2019-2025
29 companies · $943 in 2025
The $943 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $303 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.33 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $99.44 | 2024-2025 | Enhertu |
| Janssen Biotech, INC. | $93.92 | 2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $86.46 | 2024-2025 | |
| Exelixis INC. | $79.42 | 2025 | Cabometyx |
| Springworks Therapeutics, INC. | $77.89 | 2024-2025 | Ogsiveo |
| Astellas Pharma US INC | $74.99 | 2025 | |
| Blueprint Medicines Corporation | $55.10 | 2024-2025 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $48.74 | 2024-2025 | Lynparza, Calquence |
| Kite Pharma, INC. | $46.30 | 2024-2025 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $45.19 | 2025 | Opdivo |
| Sobi, INC | $43.68 | 2025 | |
| Stemline Therapeutics INC. | $41.78 | 2024 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $41.36 | 2025 | Ninlaro |
| Array Biopharma INC | $38.88 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Beigene USA, INC. | $37.51 | 2024-2025 | Tevimbra, Brukinsa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $35.83 | 2025 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $30.70 | 2025 | |
| Celgene Corporation | $29.93 | 2024 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $28.01 | 2024 | Ultomiris |
| Puma Biotechnology, INC. | $27.85 | 2025 | |
| Aveo Pharmaceuticals, INC. | $26.99 | 2025 | |
| Genmab U.S., INC. | $22.64 | 2025 | Epkinly |
| Beone Medicines USA, INC. | $22.30 | 2025 | Tevimbra |
| Gilead Sciences, INC. | $21.11 | 2025 | Trodelvy |
| Taiho Oncology, INC. | $20.81 | 2024 | |
| Lilly USA, LLC | $18.67 | 2025 | Jaypirca, Verzenio |
| Pharmacosmos Therapeutics INC. | $17.69 | 2025 | Monoferric |
| Legend Biotech USA INC. | $16.90 | 2025 | Carvykti |
| Immunocore Limited | $16.23 | 2025 | Kimmtrak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhila Thammineni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.